Xencor Company Profile (NASDAQ:XNCR)

Analyst Ratings

Consensus Ratings for Xencor (NASDAQ:XNCR) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.67 (27.51% upside)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Leerink SwannReiterated RatingOutperform$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016WedbushReiterated RatingOutperform$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015MLV & Co.Reiterated RatingBuy$22.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit Suisse Group AGInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Xencor (NASDAQ:XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016Q216($0.18)$7.43 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.17)($0.19)$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015($0.22)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3 14($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014($0.19)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xencor (NASDAQ:XNCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.35)($0.21)($0.26)
Q2 20164($0.36)($0.23)($0.28)
Q3 20164($0.37)($0.24)($0.29)
Q4 20164($0.29)$0.06($0.19)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.28)($0.28)($0.28)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xencor (NASDAQ:XNCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xencor (NASDAQ:XNCR)
DateHeadline
07/28/16 09:03 AMShould You Buy Xencor (XNCR) Ahead of Earnings? -
07/26/16 07:56 PMCan Shares Of Xencor, Inc. (NASDAQ:XNCR) Hit $27? - Investor Newswire
07/26/16 07:18 AMXencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016 - [at noodls] - MONROVIA, Calif., July 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
07/23/16 09:01 AMXencor, Inc. (XNCR) Current Analyst Ratings - Fiscal Standard
07/21/16 07:44 PMEarnings Focus and Crowd Sourced Sentiment Review for Xencor, Inc. (NASDAQ:XNCR) - TGP
07/21/16 07:44 PMAre Analysts Bearish Xencor Inc (NASDAQ:XNCR) After Last Week? - Consumer Eagle
07/19/16 07:34 PMXencor, Inc. (NASDAQ:XNCR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 07:34 PMIs $27 Price Target Attainable For Xencor, Inc. (NASDAQ:XNCR)? - Investor Newswire
07/18/16 04:50 AMStock in Positive Territory for the Quarter: Xencor, Inc. (NASDAQ:XNCR) - Engelwood Daily
07/18/16 04:50 AMTrading Performance and Target Watch for Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph
07/18/16 04:50 AMShare Performance Summary for: Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph
07/16/16 10:32 AMShares Experiencing a Downtrend: Xencor, Inc. (NASDAQ:XNCR) - TGP
07/16/16 10:32 AMBroker Outlook For Xencor, Inc. (XNCR) - Fiscal Standard
07/13/16 10:12 AMWhy Xencor (XNCR) is Poised to Beat Earnings Estimates Again
07/12/16 07:36 PMXencor, Inc. (NASDAQ:XNCR) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 07:36 PMStrong Sell Calls For Xencor, Inc. (NASDAQ:XNCR) At 0 - Investor Newswire
07/12/16 08:30 AMThe Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor -
07/11/16 07:12 PMStock on the Rise for the Quarter: Xencor, Inc. (NASDAQ:XNCR) - Engelwood Daily
07/11/16 07:12 PMStock Performance Rundown on: Xencor, Inc. (NASDAQ:XNCR) - Press Telegraph
07/11/16 07:12 PM1.24 is Xencor Inc's (NASDAQ:XNCR) Institutional Investor Sentiment - Press Telegraph
07/06/16 03:17 AMCan The Uptrend Continue for Xencor (XNCR)? -
07/05/16 07:45 AMCan Xencor (XNCR) Run Higher on Strong Earnings Estimate Revisions? -
06/29/16 10:02 AMXencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676
06/29/16 10:02 AMXencor Inc. (XNCR) Is Climbing After Novartis Collaboration Agreement
06/29/16 10:02 AMXencor Inc. (XNCR) Surged To A 6-Month High On Novartis Collaboration
06/29/16 04:21 AMWhy Xencor Inc's Shares Are Skyrocketing Today - Motley Fool - Motley FoolWhy Xencor Inc's Shares Are Skyrocketing TodayMotley FoolWhat: Shares of Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical focused primarily on autoimmune diseases and cancer, are up more than 35% as of 3:20 p.m. EDT after news broke that the company has signed a lucrative collaboration ...Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676PR Newswire (press release)Xencor (XNCR) Offers Update on Lead Product Candidates, Novartis (NVS) CollaborationStreetInsider.comNovartis goes bispecific with Xencor in up to $2.6B immuno-oncology dealFierceBiotechLos Angeles Times -Investor's Business Daily -BioWorld Online -BioPharma Diveall 26 news articles »
06/28/16 02:52 PMWhy Xencor Inc's Shares Are Skyrocketing Today - The signing of a lucrative partnership agreement with a pharma giant sends shares soaring.
06/28/16 01:52 PMMid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis -   Toward the end of trading Tuesday, the Dow traded up 0.82 percent to 17,281.21 while the NASDAQ climbed 1.44 percent to 4,660.74. The S&P also rose, gaining 0.96 percent to 2,019.82. Leading and Lagging Sectors On Tuesday, energy shares rose by 2.1 percent. Top gainers in the sector included EV BP Prudhoe Bay Royalty Trust (NYSE: BPT) and Pioneer Energy Services Corp (NYSE: PES). In trading on Tuesday, utilities shares rose by just 0.4 percent. Meanwhile, top losers in the sector included South Jersey Industries Inc (NYSE: SJI), down 3 percent, and Chesapeake Utilities Corporation (NYSE: CPK), down 2 percent. Top Headline Gannett Co Inc (NYSE: GCI) announced its plans to acquire ReachLocal Inc. (NASDAQ: RLOC) for $4.60 per share. Gannett projects the deal to close in the third quarter. Equities Trading UP Xencor Inc (NASDAQ: XNCR) shares shot up 36 percent to $17.03 after the company announced a strategic ...Full story available on Benzinga.com
06/14/16 07:09 AMXencor to Host Analyst Day and Webcast on June 28, 2016 - [at noodls] - MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
06/06/16 04:47 PMETF’s with exposure to Xencor, Inc. : June 6, 2016 -
05/28/16 02:27 PMXencor, Inc. (NASDAQ:XNCR) Impact Score At 0 - Investor Newswire - Xencor, Inc. (NASDAQ:XNCR) Impact Score At 0Investor NewswireAlpha One explored various online articles released on Xencor, Inc. (NASDAQ:XNCR), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/25/16 02:18 PMXencor, Inc. (NASDAQ:XNCR) EPS Estimate At $-0.3 - Stocks Daily - Xencor, Inc. (NASDAQ:XNCR) EPS Estimate At $-0.3Stocks DailyThe EPS projection of Xencor, Inc. (NASDAQ:XNCR) for quarter ended 2016-09-30 is $-0.3. A week earlier, the EPS target was $-0.3 against target of $-0.3, a month earlier. This target stood at $-0.3 60 days ago against estimate of $-0.3 90 days earlier.Were Analysts Bullish Xencor Inc (NASDAQ:XNCR) This Week?Wall Street Hints and Newsall 2 news articles »
05/24/16 12:39 AMEarnings Review and Stock Rundown for Xencor, Inc. (NASDAQ:XNCR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Xencor, Inc. (NASDAQ:XNCR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Xencor, Inc. (NASDAQ:XNCR) to post ...and more »
05/23/16 07:06 AMXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : May 23, 2016 -
05/18/16 11:32 AMXencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference - [at noodls] - MONROVIA, Calif., May 18, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
05/18/16 11:03 AM12:03 pm Xencor presents complete data results from phase 1a first-in-human study for XmAb7195 at the American Thoracic Society International Conference, XmAb7195 generally 'well tolerated' -
05/17/16 07:33 PMShare Recap and Earnings Focus on Xencor, Inc. (NASDAQ:XNCR) - Wall Street Hints and News - Share Recap and Earnings Focus on Xencor, Inc. (NASDAQ:XNCR)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Xencor, Inc.and more »
05/17/16 07:42 AMXencor to Present at Upcoming Investor Conferences - [at noodls] - MONROVIA, Calif., May 17, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
05/11/16 02:34 PMConsensus Rating Review for Xencor, Inc. (NASDAQ:XNCR) - B.O.D.Y Confidential - Consensus Rating Review for Xencor, Inc. (NASDAQ:XNCR)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Xencor, Inc. (NASDAQ:XNCR). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/11/16 09:22 AMXencor, Inc. :XNCR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 12:47 AMAfter Last Week What Do Analysts Think Of Xencor, Inc. (XNCR) - Share Trading News - After Last Week What Do Analysts Think Of Xencor, Inc. (XNCR)Share Trading News05/06/2015 – Xencor, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 14 price target on the stock. The share price of Xencor, Inc. (XNCR) was up +0.62% during the last trading session, with a day high of 11.44.
05/07/16 12:04 PMXENCOR INC Financials -
05/05/16 07:40 PMXencor Inc (XNCR) Drops 7.06% on May 04 - Equities.com - Xencor Inc (XNCR) Drops 7.06% on May 04Equities.comXencor Inc (XNCR) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 7.06% to $11.06, a loss of $-0.84 per share. Starting at an opening price of $11.79 a share, the stock traded between $10.96 and $11.79 over the ...Xencor Inc (XNCR) Forecasted to Post Q1 2017 Earnings of ($0.26) Per ShareWeb Breaking NewsBroker Roundup For Xencor, Inc. (XNCR)Share Trading Newsall 5 news articles »
05/05/16 02:33 PMXencor Inc (XNCR) is Trading Lower on Unusual Volume for May 03 - Equities.com - Xencor Inc (XNCR) is Trading Lower on Unusual Volume for May 03Equities.comXencor Inc (XNCR) experienced unusually high volume on May. 03, as the stock lost 3.49% to a closing price of $11.90. The stock saw 333,721 shares trade hands over the course of the day on 3,001 trades. Given that the stock's average daily volume over ...Were Analysts Bearish Xencor Inc (NASDAQ:XNCR) This Week?B.O.D.Y Confidentialall 3 news articles »
05/04/16 02:32 PMAverage Analyst Rating for Xencor, Inc. (NASDAQ:XNCR) - B.O.D.Y Confidential - Average Analyst Rating for Xencor, Inc. (NASDAQ:XNCR)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Xencor, Inc. (NASDAQ:XNCR) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 02:32 PMAnalysts See 62% Gains Ahead For XBI - Three of XBI's underlying holdings with notable upside to their analyst target prices are Xencor, Inc (XNCR), Vanda Pharmaceuticals Inc (VNDA), and Alder Biopharmaceuticals Inc (ALDR). Although XNCR has traded at a recent price of $11.79/share, the average ...
05/03/16 01:53 PMETF’s with exposure to Xencor, Inc. : May 3, 2016 -
05/03/16 12:48 AMNorthwest Bio Heading North, PRTK To Report Data In June, FLML Gets FDA Nod - TRVN closed Monday's trading at $7.63, down 2.05%. Xencor Inc. (XNCR) expects full results from a phase Ia trial of XmAb7195 for the treatment of severe asthma and allergic diseases this quarter. A phase I trial with a subcutaneous formulation of XmAb7195 ...
05/02/16 03:57 PMXencor reports 1Q loss -
05/02/16 03:30 PMXencor Reports First Quarter 2016 Financial Results - [at noodls] - MONROVIA, Calif., May 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...

Social

About Xencor

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XNCR
  • CUSIP:
Key Metrics:
  • Previous Close: $18.78
  • 50 Day Moving Average: $16.620
  • 200 Day Moving Average: $13.518
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $756.43M
  • Beta: 2.26
  • Current Year EPS Consensus Estimate: $-0.77 EPS
  • Next Year EPS Consensus Estimate: $-1.00 EPS
Additional Links:
Xencor (NASDAQ:XNCR) Chart for Thursday, July, 28, 2016